Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Distribution: Tissue Binding

Drug Distribution: Tissue Binding

Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...

Protein-Drug Binding: Mechanism and Kinetics

Protein-Drug Binding: Mechanism and Kinetics

Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...

Drug-Receptor Bonds

Drug-Receptor Bonds

Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...

Drug Distribution: Plasma Protein Binding

Drug Distribution: Plasma Protein Binding

Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...

Drug-Receptor Interactions

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.

Tissue-Drug Binding: Localization of Drugs and its Significance

Tissue-Drug Binding: Localization of Drugs and its Significance

Body tissues, comprising approximately 40% of the body weight, are crucial in drug distribution and localization. These tissues can serve as drug storage sites, competing with plasma binding sites for drug molecules.
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Histidine Cluster in the Cytoplasmic Domain of the Na-H Exchanger NHE1 Confers pH-sensitive Phospholipid Binding and Regulates Transporter Activity.

The Journal of biological chemistry·2016

Same author

Distribution of formins in cardiac muscle: FHOD1 is a component of intercalated discs and costameres.

European journal of cell biology·2015

Same author

Highly sensitive and fast detection of propane-butane using a 3 μm quantum cascade laser.

Applied optics·2013

Same author

Electrostatics control actin filament nucleation and elongation kinetics.

The Journal of biological chemistry·2013

Same author

Considering protonation as a posttranslational modification regulating protein structure and function.

Annual review of biophysics·2013

Same author

FHOD1 is a combined actin filament capping and bundling factor that selectively associates with actin arcs and stress fibers.

Journal of cell science·2013

Search research articles

Related Experiment Video

Updated: Jun 22, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Transient binding patches: a plausible concept for drug binding.

Heino Prinz¹, André Schönichen

¹Max-Planck-Institut für Molekulare Physiologie, Otto-Hahn-Str. 11, 44227, Dortmund, Germany, heino.prinz@mpi-dortmund.mpg.de.

Journal of Chemical Biology

|July 2, 2009

Summary

This study introduces new models for analyzing drug dose-response curves, challenging the traditional 1:1 binding assumption for inhibitors. The findings suggest a multi-step binding process, improving the analysis of inhibitor interactions with proteins like phosphatases.

More Related Videos

Microfluidic On-chip Capture-cycloaddition Reaction to Reversibly Immobilize Small Molecules or Multi-component Structures for Biosensor Applications

Microfluidic On-chip Capture-cycloaddition Reaction to Reversibly Immobilize Small Molecules or Multi-component Structures for Biosensor Applications

Published on: September 23, 2013

Related Experiment Videos

Last Updated: Jun 22, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Microfluidic On-chip Capture-cycloaddition Reaction to Reversibly Immobilize Small Molecules or Multi-component Structures for Biosensor Applications

Microfluidic On-chip Capture-cycloaddition Reaction to Reversibly Immobilize Small Molecules or Multi-component Structures for Biosensor Applications

Published on: September 23, 2013

Area of Science:

Biochemistry
Pharmacology
Enzyme kinetics

Background:

Traditional analysis of drug dose-response curves uses four-parameter fits, yielding IC(50), background, amplitude, and Hill coefficient.
Hill coefficients not equal to 1 often contradict the assumption of 1:1 competition between inhibitors and targets.

Purpose of the Study:

To propose and validate alternative models for analyzing inhibitor dose-response curves that account for non-stoichiometric binding.
To investigate a stepwise binding mechanism where inhibitors may bind to larger "patches" on proteins rather than specific 1:1 sites.

Main Methods:

Developed three computable models based on a stepwise binding concept.
Fitted these models to 1,282 phosphatase dose-response curves.
Utilized microcalorimetry to directly measure inhibitor binding to vaccinia virus VH1-related (VHR) phosphatase.

Main Results:

The new models successfully fitted the phosphatase dose-response data, requiring only four parameters: equilibrium dissociation constant (K(D)), background, amplitude, and a compound interaction factor.
Demonstrated that inhibitors may not follow a 1:1 stoichiometry for specific inhibition.
Microcalorimetry confirmed multiple inhibitor binding to VHR phosphatase, with equilibrium constants aligning with those from inhibition curves.

Conclusions:

The proposed models offer a more accurate representation of inhibitor-protein interactions, especially when non-1:1 binding occurs.
This approach enhances the understanding of drug mechanisms and improves the analysis of enzyme inhibition data.
The findings have implications for drug discovery and development by providing a refined method for characterizing inhibitor efficacy.